risperiDONE
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
RisperDAL Consta | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 25 mg/2 weeks, 37.5 mg/2 weeks, 50 mg/2 weeks | ||||
RisperDAL | SOLUTION, ORAL | 1 mg/mL | ||||
Perseris | SUSPENSION, EXTENDED RELEASE, INJECTABLE | 90 mg, 120 mg | ||||
Uzedy | SUSPENSION, SUBCUTANEOUS | 50 mg, 75 mg, 150 mg, 250 mg | ||||
Uzedy | SUSPENSION, SUBCUTANEOUS | 100 mg, 125 mg, 200 mg | ||||
RisperDAL M-Tab | TABLET, DISINTEGRATING, ORAL | 0.5 mg, 1 mg, 2 mg | ||||
RisperDAL | TABLET, ORAL | 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg |
Uzedy: Restricted to use by psychiatrists for patients who qualify for long-acting antipsychotic medication per the guidelines of the Uzedy Free Dose Program.
Currently, the 100 mg (dosed once monthly) and 200 mg (once every 2 months) strengths will be available in the program. The 125 mg dose will not generally be available.
Other dosage forms are considered non-formulary unless the Uzedy Free Dose Program is updated to included these strengths.
RisperDAL Consta (extended release injection) - Currently remains Formulary (June 2024). Transitioning to Uzedy program described above.
RisperDAL M Tabs (risperiDONE disinigrating tablets): Restricted to patients unable to swallow an oral tablet. Otherwise interchange with regular RisperDAL tablets at the same strength.
Perseris: Non-Formulary. Alternative long-acting antipsychotics available on formulary.
.
Reviewed: October 2023 (Uzedy)
Updated: April 2021 (Perseris), October 2023 (RisperDAL Consta)
Risperidone Long-Acting Injection (Uzedy)